Tiny study probes how COVID shots alter immune cell activity

NCT ID NCT05655351

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed early-phase study looked at how mRNA COVID-19 vaccines (Pfizer or Moderna) affect certain immune cells called monocytes in people of different ages. Researchers measured changes in reactive oxygen species (a type of cell activity) and a blood protein called AngII before and after vaccination. The study included 30 healthy adults split into three age groups: under 30, 30-60, and over 60. The goal was to understand the vaccine's biological effects, not to test its safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mRNA COVID-19 vaccine (Pfizer or Moderna)
What this could lead to: If successful, this could help explain how the vaccine affects immune cells and why responses vary by age.
What could go wrong: This is a very small, early-stage study with only 30 participants. It measures lab markers, not health outcomes, so results may not lead to direct medical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONAVIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease Coronaviridae infectious disease COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONAVIRUS INFECTIONS

Contacts and locations

Locations

CHU de Nîmes, Hôpital Universitaire Caremeau

Nîmes, France, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.